Peptides in Michigan: Research, Regulation and Where the Law Stands

Search interest in "peptide therapy Michigan" usually reflects a practical question: what governs peptide products in the state, and who is responsible for enforcing it? The answer is layered. The most consequential rules — whether a peptide is an approved drug, whether it may be compounded, and how a research chemical is labelled — are federal. Michigan law sits on top of that, governing who holds a licence to prescribe, dispense or compound, and how pharmacies operating in or shipping into the state are inspected.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision. It is also not legal advice. Nothing here is a verdict that any particular peptide, clinic or supplier is legal or illegal in Michigan; that determination depends on facts, product identity and the agency doing the asking.

The federal layer sets most of the rules

In the United States, a peptide product falls into one of a few regulatory buckets, and the bucket determines nearly everything else.

1. FDA-approved peptide drugs

A substantial number of peptides have been approved as drugs after review of manufacturing, safety and efficacy data. A review of the 2017 approval cohort catalogued the peptide products cleared by the FDA that year and described the chemistry and development pathways behind them, illustrating that peptides are a mainstream and expanding drug class rather than a fringe category (PMID 29735913). Approved peptide medicines — including GLP-1 receptor agonists such as semaglutide, liraglutide and the dual agonist tirzepatide — carry FDA-reviewed labelling, defined indications, and a formal adverse-event reporting pathway.

2. Research-use-only (RUO) material

A second category is material sold and labelled for laboratory research only. RUO labelling is a statement about intended use, not a quality certification and not an approval. Such material has not been reviewed by the FDA for human administration, and its identity, purity and sterility are not verified by any regulator as a condition of sale. A review of approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance noted the gap between the evidence base for approved products and the far thinner data supporting unapproved peptides circulating in sport and wellness settings (PMID 41966639). That evidence gap exists identically in Michigan and in every other state, because it is a property of the compounds and the literature, not of geography.

3. Compounded preparations: the 503A/503B distinction

Compounding is regulated under two sections of the Federal Food, Drug, and Cosmetic Act, and the difference matters more than most readers expect.

Neither category produces an FDA-approved drug. Compounded preparations are exempt from premarket approval, not endorsed by it. Analytical work on follow-on GLP-1 polypeptide products examined how manufacturing route and compounding practice affected product properties and quality attributes, and reported differences between products that shared a nominal active ingredient (PMID 39379664). Separately, a real-world study of compounded semaglutide reported weight and body-composition outcomes in a clinical setting, illustrating that outcome data on compounded products exist but are observational rather than derived from the approval pathway (PMID 39776038).

A further federal wrinkle: the FDA's ability to permit compounding of a copy of an approved drug is tied to shortage status. When a drug is removed from the shortage list, the compounding allowance associated with that shortage changes. This is a federal determination, not a state one, and it has driven much of the recent churn in GLP-1 compounding across all states including Michigan.

What is specific to Michigan

Michigan does not, on the available public record, maintain a peptide-specific statute or a Board of Pharmacy rule that singles out peptides as a distinct class. The structures that apply are the general ones.

• Michigan Department of Licensing and Regulatory Affairs (LARA) houses the state's health professional boards through its Bureau of Professional Licensing.
• The Michigan Board of Pharmacy licenses pharmacies and pharmacists, licenses out-of-state pharmacies that ship into Michigan, and oversees compounding practice within the state.
• The Michigan Board of Medicine and the Board of Osteopathic Medicine and Surgery license physicians and govern professional conduct, including prescribing.
• The Michigan Public Health Code (Act 368 of 1978) is the underlying statute for health occupation licensing and controlled substance scheduling in the state.

Where a specific Michigan rule number, effective date or peptide-specific policy would be needed to make a definite claim, this page does not supply one, because no such peptide-specific provision could be verified. Readers seeking the current text of a rule are better served by LARA's published rules and the Michigan Compiled Laws directly than by any secondary summary, including this one. Rules change; a state page frozen in time is not a substitute for the primary source or for a Michigan-licensed attorney.

Telehealth prescribing

Telehealth prescribing in Michigan is governed by a combination of state licensure requirements — a prescriber generally must hold appropriate licensure to treat a patient located in the state — and federal rules for any controlled substance involved. Most peptide drugs discussed in weight-management and metabolic contexts, including GLP-1 receptor agonists, are not controlled substances, so the federal controlled-substance telemedicine framework is typically not the operative constraint. The operative constraints are professional licensure, the existence of a valid prescriber-patient relationship, and the standard of care enforced by the state medical boards.

Adverse Events in Approved Peptide Drugs: What Studies Report

Regulatory categories exist because of safety data. The pharmacovigilance literature on approved peptide drugs gives a sense of what post-marketing surveillance has surfaced.

Gastrointestinal signals

A disproportionality study of the FDA Adverse Event Reporting System (FAERS) examined gastrointestinal adverse reactions across GLP-1 receptor agonists and reported class-wide gastrointestinal reporting signals, with differences between individual agents (PMID 36568085). A separate FAERS analysis focused on semaglutide reported gastrointestinal events as a prominent category in the submitted reports (PMID 36339230). A further real-world disproportionality analysis of semaglutide's post-marketing data described the overall signal profile drawn from spontaneous reports (PMID 38943656).

Metabolic, nutritional and pancreatic signals

Researchers examining metabolic and nutritional adverse events across GLP-1 receptor agonists reported signals in that category in pharmacovigilance data (PMID 39040467). Another analysis combined a case series with real-world pharmacovigilance data to examine the association between different GLP-1 receptor agonists and acute pancreatitis (PMID 39605914).

Psychiatric signals

An analysis of individual case safety reports submitted to the European EudraVigilance database examined psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide (PMID 38265519). A FAERS-based study explored the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviours (PMID 38355513). Both study designs rest on spontaneous reporting, which the authors of such analyses routinely note cannot establish causation, incidence or comparative risk.

Tirzepatide

A pharmacovigilance analysis of the FAERS database characterised the real-world safety profile of tirzepatide as reflected in submitted reports (PMID 39141075).

These studies describe reporting patterns in surveillance databases. They do not describe what happens to any individual, and they are not a basis for personal decisions. Disproportionality signals are hypothesis-generating.

Who enforces what

1. FDA — drug approval, labelling, compounding oversight under 503A/503B, action against unapproved drug marketing and false claims, and shortage-list determinations.
2. FTC — advertising and marketing claims about health products.
3. DEA — controlled substances only; most peptides discussed in this context are not scheduled.
4. Michigan Board of Pharmacy (via LARA) — pharmacy and pharmacist licensure, in-state compounding practice, licensure of out-of-state pharmacies shipping into Michigan.
5. Michigan Boards of Medicine and Osteopathic Medicine and Surgery (via LARA) — prescriber licensure, professional conduct, standard-of-care discipline.
6. Michigan Attorney General — consumer protection matters under state law.

Why "research use only" is not a state-level question

A recurring misconception is that a given state permits or forbids RUO peptide sales. RUO labelling is a federal construct describing intended use. Material sold under that label has not been evaluated for human administration anywhere in the country. The review of approved and unapproved peptides in musculoskeletal and athletic contexts underscored that unapproved compounds frequently lacked the controlled human data available for approved products (PMID 41966639). No Michigan rule changes that underlying evidence position.

Practical framing for readers researching Michigan

Anyone trying to understand the status of a specific peptide product in Michigan is usually asking three separate questions at once: is this compound an approved drug; if not, is it being prepared by a facility operating lawfully under 503A or 503B; and is the person prescribing it appropriately licensed in Michigan. Those are answered by different bodies of law and different regulators. Conflating them produces most of the confusion visible in online discussion.

Again, and finally: this page describes regulatory structure and summarises published findings. It is not legal advice and not medical advice. Questions about a specific product, prescriber or pharmacy in Michigan are properly directed to a Michigan-licensed attorney, to LARA's Bureau of Professional Licensing, or to a licensed physician.

References

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• 2017 FDA Peptide Harvest (Pharmaceuticals, 2018)
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)
• Weight loss and body composition after compounded semaglutide treatment in a real world setting (Diabetes, Obesity & Metabolism, 2025)
• Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database (Frontiers in Endocrinology, 2022)
• Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (Frontiers in Public Health, 2022)
• A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data (Journal of Diabetes Investigation, 2024)
• Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events (Frontiers in Pharmacology, 2024)
• Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis (Frontiers in Pharmacology, 2024)
• Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database (International Journal of Clinical Pharmacy, 2024)
• Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database (BMC Medicine, 2024)
• The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (Journal of Endocrinological Investigation, 2024)